Quantum Biopharma Ltd. Class B Subordinate Voting Shares
QNTMQuantum Biopharma Ltd. is a biotechnology company focused on developing and commercializing innovative therapies in the biopharmaceutical sector. The company aims to leverage advanced scientific research to create targeted treatments, particularly in areas such as neurodegenerative diseases and other unmet medical needs. Its Class B subordinate voting shares (QNTM) represent equity ownership and voting rights within the company, offering investors opportunities to participate in its growth and development efforts.
Company News
Quantum BioPharma announced completion of oral dosing in 180-day repeated dose toxicity and toxicokinetic studies for Lucid-21-302 (Lucid-MS), a first-in-class treatment candidate for multiple sclerosis. The studies will support the company's Investigational New Drug (IND) application with the US FDA and inform the design of a Phase 2 trial. Luci...
Quantum BioPharma announced the expiration of 53,147 warrants issued to hedge funds and confirmed October 27, 2025, as the record date for distributing contingent value rights (CVRs) related to a potential litigation settlement against financial institutions.
